Will DiaMedica Therapeutics stock go up?

According to Danelfin AI, DiaMedica Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.79%) is +1.97% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for DiaMedica Therapeutics stock?

The DiaMedica Therapeutics target price is $7.64 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold DiaMedica Therapeutics stock right now?

DiaMedica Therapeutics has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.79%) is +1.97% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether DiaMedica Therapeutics stock is a good buy .

Is DiaMedica Therapeutics undervalued right now?

Based on analysts, the average price target downside for DiaMedica Therapeutics is 0.00% (1Y). According to Danelfin AI, DiaMedica Therapeutics has today an AI Score of 5/10 (Hold Rating).

What was the price range of DiaMedica Therapeutics stock over the past 12 months?

The DiaMedica Therapeutics stock price range over the past 12 months has been $3.57 - $9.39.

What is going on with DiaMedica Therapeutics stock in the last 3 months?

The DiaMedica Therapeutics stock performance in the last quarter has been +19.00%.

Does DiaMedica Therapeutics offer dividend payments?

No, DiaMedica Therapeutics does not currently pay dividends.

What is the current market capitalization of DiaMedica Therapeutics?

DiaMedica Therapeutics's market cap is $410.59M, as of 2026-07-03 08:00.

DiaMedica Therapeutics Inc (DMAC) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

DMAC AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, DiaMedica Therapeutics Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 53% probability of outperforming the market in the next 3 months, which is 2% higher than the average probability of any stock (51%). The top positive contributors include Operating Cash Flow (Qtr Discrete) (bottom 20%, +2.86%), Chart Pattern (252d) (+2.49%), and Fundamentals Impact (Long Tail) (+1.29%), all boosting the probability. On the other hand, the main detractors are Chart Pattern (504d) (-2.04%), Fear & Greed Index (CNN) (value 31, -1.80%), and Maximum Volatility (top 20%, -1.34%), which weigh down the stock's chances. Notable data points include Alpha 1Y in the top 10% (+0.68%), indicating strong risk-adjusted returns, and Analyst Mean Price Target Upside in the top 20% (+0.67%), suggesting analyst optimism. However, Net Property, Plant & Equipment is in the bottom 10% (-0.83%), and Tangible Shareholders' Equity is in the bottom 40% (-0.73%), reflecting weak asset bases. The Earnings Countdown is -51 days (bottom 20%, +0.66%), meaning earnings were recently reported. Overall, the mixed signals—positive cash flow and technical patterns offset by high volatility and weak fundamentals—result in a balanced HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+2.86%
Stability and reliability of reported earnings
Momentum+1.23%
Direction and strength of recent price movements
Size & Liquidity+0.41%
Company size and trading liquidity

Volatility-1.34%
How much the stock price tends to fluctuate
Valuation-0.78%
How the stock is priced relative to its fundamentals
Sentiment-0.41%
How analysts and the market view the stock

DMAC probability advantage of beating the market (3M):

+1.97%

AI Score

Hold

DiaMedica Therapeutics (DMAC) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +1.97% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of DMAC (52.79%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
DMAC probability advantage of beating the market (3M)+1.97%
DMAC probability of beating the market (3M)52.79%

DMAC probability advantage of beating the market (3M): +1.97%

The AI-powered overall analysis of DiaMedica Therapeutics (DMAC) is based on the 25 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of DMAC:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Operating Cash Flow (Qtr Discrete)	-9.08		+2.86%
Technical	Chart Pattern (252d)	figure_79	N/A	+2.49%
Technical	Chart Pattern (504d)	figure_22	N/A	-2.04%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.80%
Technical	Maximum Volatility	7.99%		-1.34%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.29%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	+1.21%
Technical	Distance from KAMA (20d)	0.17%		-1.10%
Technical	Chart Pattern (180d)	figure_106	N/A	+1.00%
Fundamental	Net Property, Plant & Equipment (Net PP&E)	0.14	N/A	-0.83%
Fundamental	Upgrade to unlock			-0.73%
Technical	Upgrade to unlock			+0.73%
Technical	Upgrade to unlock			+0.68%
Sentiment	Upgrade to unlock			+0.67%
Sentiment	Upgrade to unlock			+0.66%

Rest of Alpha Signals: -1.79%

DMAC probability advantage of beating the market (3M)Total:+1.97%
DMAC AI Score

Significant changes Vs previous day

DMAC Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$7.64
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

DMAC Proven Hold Signal & Price Forecast

This is the price chart for DMAC from January 2, 2026 until today. The chart indicates, in yellow, the 97 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

DMAC Average Past Performance & Win Rate

Three months after its 1213 Hold signals since July 2026, DMAC had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

1213 Past DMAC Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+33.80%
Average Alpha				+17.66%
Win Rate (% Positive Perf.)				66.24%
% Positive Alpha				60.36%

DMAC Frequently Asked Questions

Will DiaMedica Therapeutics stock go up?
According to Danelfin AI, DiaMedica Therapeutics has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.79%) is +1.97% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for DiaMedica Therapeutics stock?
Is it a good time to buy, sell, or hold DiaMedica Therapeutics stock right now?
Is DiaMedica Therapeutics undervalued right now?
What was the price range of DiaMedica Therapeutics stock over the past 12 months?
What is going on with DiaMedica Therapeutics stock in the last 3 months?
Does DiaMedica Therapeutics offer dividend payments?
What is the current market capitalization of DiaMedica Therapeutics?

DiaMedica Therapeutics Inc Company Profile

DiaMedica Therapeutics Inc., is a clinical stage, biopharmaceutical entity committed to transforming the health outcomes of individuals affected by severe illnesses, particularly acute ischemic stroke. The company's primary concentration lies within the realms of neurological disorders and cardio-renal disease. Its spearheading candidate for therapeutical intervention is DM199, an innovative pharmaceutical application of recombinant kallikrein-1 protein; this novel solution aims towards addressing acute ischemic stroke alongside other vascular pathologies. Additional research and development efforts have given birth to DM300, currently in its preclinical developmental stage designed to tackle inflammatory diseases. With roots stretching back to the year 2000 as DiaMedica Inc., the organization underwent a rebranding process in December 2016 and emerged as DiaMedica Therapeutics Inc., that it identifies with today. The firm takes pride in its Minneapolis, Minnesota headquarters where it continues its quest for advancing medicinal progress.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:301 Carlson Parkway, Suite 210, Minneapolis
Employees:35
Website:diamedica.com

Pros

Proprietary drug candidate with broad therapeutic potential

High regulatory barriers to entry for novel therapeutics

Potential for market exclusivity through intellectual property

Addressing unmet medical needs in target patient populations

Potential for orphan drug designation benefits

Cons

High capital expenditure for clinical development programs

Binary risk of drug candidate clinical trial failure

Concentration risk in a single lead therapeutic asset

Extensive and lengthy regulatory approval pathway

Competition from existing therapies and pipeline candidates

Company	AI Score	Compare
CALCCalciMedica Inc
CYPHLeap Therapeutics Inc
KALAKALA BIO Inc
KLRSKalaris Therapeutics Inc
KODKodiak Sciences Inc

Company	AI Score	Compare
CALCCalciMedica Inc
CYPHLeap Therapeutics Inc
KALAKALA BIO Inc
KLRSKalaris Therapeutics Inc
KODKodiak Sciences Inc

DMAC Stock AI Analysis